Peptide-like compounds that inhibit coronaviral 3CL and...

Details Peptide-like compounds that inhibit coronaviral 3CL and... Peptide-like compounds that inhibit coronaviral 3CL and...

2005-02-25

2008-12-09

Krass, Frederick (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S011400, C514S424000

Reexamination Certificate

active

07462594

ABSTRACT:
This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (II). Each variable is defined in the specification.

REFERENCES:
patent: 5856530 (1999-01-01), Webber et al.
patent: 5962487 (1999-10-01), Webber et al.
patent: 6214799 (2001-04-01), Webber et al.
patent: 6355807 (2002-03-01), Tian et al.
patent: 6362166 (2002-03-01), Webber et al.
patent: 6514997 (2003-02-01), Dragovich et al.
patent: 6531452 (2003-03-01), Dragovich et al.
patent: 6534530 (2003-03-01), Dragovich et al.
patent: 2001/0047006 (2001-11-01), Dragovich et al.
patent: 2002/0006943 (2002-01-01), Johnson, Jr. et al.
patent: 2002/0133020 (2002-09-01), Tian et al.
patent: 2006/0014821 (2006-01-01), He et al.
patent: WO 97/43305 (1997-11-01), None
patent: WO 99/57135 (1999-11-01), None
Dragovich et al., “Structure-Based Design of Irreversible, Tripeptidyl Human Rhinovirus 3C Protease Inhibitors Containing N-Methyl Amino Acids”, Bioorganic & Medicinal Chemistry Letters, 9 (1999) 2189-2194.
Dragovich et al., “Structure-Based Design of Ketone-Containing, Tripeptidyl Human Rhinovirus 3C Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 10 (2000) 45-48.
Dragovich et al., “Solid-phase Synthesis of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 1: Optimization of Tripeptides Incorporating N-terminal Amides”, Bioorganic & Medicinal Chemistry 7 (1999) 589-598.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 7: Structure—Activity Studies of Bicyclic 2-Pyridone-Containing Peptidomimetics”, Bioorganic & Medicinal Chemistry Letters 12 (2002) 733-738.
Dragovich et al., “Synthesis of an Optically Active, Bicyclic 2-Pyridone Dipeptide Mimetic”, J. Org. Chem. 2002, 67,741-746.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure—Activity Studies”, J. Med. Chem. 1998, 41, 2806-2818.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure—Activity Studies”, J. Med. Chem. 1998, 41, 2819-2834.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure—Activity Studies of Ketomethylene-Containing Peptidomimetics”, J. Med. Chem. 1999, 42, 1203-1212.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1Lactam Moieties as L-Glutamine Replacements”, J. Med. Chem. 1999, 42, 1213-1224.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure—Activity Studies of Orally Bioavailable, 2-Pydridone-Containing Peptidomimetics”, J. Med. Chem. 2002, 45, 1607-1623.
Dragovich et al., “Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics”, J. Med. Chem. 2003, 46, 4572-4585.
Johnson et al., “Structure-Based Design of a Parallel Synthetic Array Directed Toward the Discovery of Irreversible Inhibitors of Human Rhinovirus 3C Protease”, J. Med. Chem. 2002, 45, 2016-2023.
Matthews et al., “Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes”, Proc. Natl. Acad. Sci USA, vol. 96, pp. 11000-11007, Sep. 1999.
Reich et al., “Substituted Benzamide Inhibitors of Human Rhinovirus 3C Protease: Structure-Based Design, Synthesis, and Biological Evaluation”, J. Med. Chem. 2000, 43, 1670-1683.
Tian et al., “An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester”, Tetrahedron Letters, 42, 2001, 6807-6809.
Wang, “Design of rhinovirus protease inhibitors for the treatment of the common cold”, Drugs of the Future, 2000, 25(3):279-286.
Webber et al., “Design and Synthesis of Irreversible Depsipeptidyl Human Rhinovirus 3C Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 11, 2001, 2683-2686.
Caulfield et al., “Parallel Solid-Phase Synthesis of Peptidyl Michael Acceptors”, J. Comb. Chem. 2:600-603, 2000.
Jenwitheesuk et al., “Identifying Inhibitors of the SARS Coronavirus Proteinase”, Bioorganic & Medicinal Chemistry Letters 13:3989-3992, 2003.

Affiliated with

Also associated with

Rating

Peptide-like compounds that inhibit coronaviral 3CL and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide-like compounds that inhibit coronaviral 3CL and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-like compounds that inhibit coronaviral 3CL and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4032427